Raising Funds for Business Expansion through Convertible Bonds with Stock Acquisition Rights and Other Instruments
First written in FY2020. 2 of 3 entries say "Restated". Latest entry: FY2021-Q2.
3 other companies' latest entry also says "Restated".
- FY2021-Q2RestatedAnnual report
「With respect to funding, in March 2020 the company raised ¥1 billion through the issuance of its First Series Unsecured Convertible Bonds with Share Acquisition Rights, allocated to THE KENKOU FUTURE Investment Limited Partnership, whose general partner is With Partners Co., Ltd., and Sanwa Starch Co., Ltd. The company has secured the necessary business funds.」
The company has reconfirmed its explanation that it raised ¥1 billion in March 2020 through convertible bonds with share acquisition rights and secured the necessary business funds. - FY2021-Q1RestatedAnnual report
「With respect to funding, in March 2020 the company raised ¥1 billion through the issuance of its First Series Unsecured Convertible Bonds with Share Acquisition Rights, allocated to THE KENKOU FUTURE Investment Limited Partnership, whose general partner is With Partners Co., Ltd., and Sanwa Starch Co., Ltd. The company has secured the necessary business funds.」
The company has reconfirmed its explanation that it raised ¥1 billion in March 2020 through convertible bonds with share acquisition rights and secured the necessary business funds. - FY2020First statedAnnual report
「In March 2020, the company raised funds through a private placement of its First Series Unsecured Convertible Bonds with Share Acquisition Rights and 21st Series Share Acquisition Rights. The funds raised will be used mainly to expand the applications of PXB mice and PXB-cells, conduct consortium activities to acquire customers, fund business alliances with CROs, develop and refurbish production facilities, and pay outsourcing costs.」
The company raised ¥1 billion through a private placement of convertible bonds with share acquisition rights and other instruments, and used the funds to expand applications, conduct consortium activities, form CRO alliances, and develop production facilities.